Page 22 - Generation Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioPharma

  First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year   THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020   The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.   At the end of December 2020, Oxurion had cash, cash equiva...

  First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year   THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020   The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.   At the end of December 2020, Oxurion had cash, cash equiva...

DGAP-News: BB BIOTECH AG / Key word(s): Annual Results/Dividend BB BIOTECH AG: Vaccines leading the way out of the pandemic - increased dividend of CHF 3.60 proposed 22.01.2021 / 07:00 Media release as of January 22, 2021 Portfolio of BB Biotech AG as of December 31, 2020 Vaccines leading the way out of the pandemic - increased dividend of CHF 3.60 proposed BB Biotech performed well in 2020 in a volatile market environment. The biotech sector made significant strides, leading the effort against the SARS-CoV-2 virus pandemic through approved mRNA vaccines and therapeutic antibodies. M&A activ...

Generation Bio Announces Pricing of Public Offering January 06, 2021 21:24 ET | Source: Generation Bio Co. Generation Bio Co. Cambridge, Massachusetts, UNITED STATES CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of a public offering of 8,000,000 shares of its common stock at a public offering price of $24.50 per share. In addition, Generation Bio has granted the underwriters a 30-day option to purchase ...